AI Offers New Pathways to Strengthen Site Leadership
Artificial intelligence can help identify key opinion leaders in emerging markets, improving site influence, patient engagement, and trial success.
Gen Li, PhD, MBA, president of Phesi, discussed results from the company's analysis on global inequity in breast cancer development in a recent video interview with Applied Clinical Trials.
- Geographic concentration of breast cancer trial leaders is in the US and China.
- Operational barriers in lower-income countries are due to traditional business models.
- AI and machine learning can implement a more patient-centric approach.
Identifying local leaders is crucial, and AI can help redistribute trial workloads and improve recruitment by activating new sites.
Author's summary: AI improves site leadership in underserved regions.
More News
- Novartis to Acquire Avidity Biosciences for US$12 Billion in Rare-Disease Push
- Pastors and professionals
- Grokipedia launches after brief crash, accused of copying Wikipedia content - Tech Digest
- African tax leaders meet in Uganda to tackle effective taxation of the wealthy - Institute of Development Studies
- In Review: Big Ass Sword by Andreas Butzbach
- AI tool paints bigger picture of global impact of millions of research grants, papers and patents
- GSK secures rights to Syndivia’s ADC asset for prostate cancer
- Fraternity and hope strengthen relations between Catholics and Anglicans
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- SELUTION DeNovo Trial Demonstrates Non-Inferiority of Drug-Eluting Balloon to Standard-of-Care for In-Stent Restenosis: Late-Breaking Results from TCT 2025